Breaking news

Novo Partners With Anthropic To Accelerate AI-Driven Drug Development

by THEFUTURE.TEAM

September 17, 2026

Danish pharmaceutical group Novo, formerly Novo Nordisk and best known for Ozempic, has partnered with Anthropic to accelerate drug development using artificial intelligence.

AI Expands Into Novo’s R&D

Under the agreement, Novo will use Anthropic’s models and Claude Science across its research and development operations. The company said the tools will support scientific reasoning, improve productivity and help researchers explore new approaches to understanding human biology and drug mechanisms.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,” Novo President and CEO Mike Doustdar said in a press release.

Anthropic CEO Dario Amodei said access to advanced AI models could help researchers shorten research timelines and improve drug discovery.

Novo Builds A Broader AI Strategy

The Anthropic partnership follows Novo’s separate agreement with OpenAI in April to use AI for analyzing complex datasets, identifying potential drugs and reducing the time between research and patient access.

Novo is also involved in Denmark’s AI infrastructure. In 2024, the Novo Nordisk Foundation partnered with Nvidia and the Export and Investment Fund of Denmark to establish the Danish Centre for AI Innovation, which operates the Gefion supercomputer.

Anthropic Expands In Life Sciences

Anthropic has also been expanding its presence in healthcare and pharmaceuticals. In May 2026, it announced a collaboration with Bristol Myers Squibb covering research, clinical development, manufacturing, commercial and corporate functions.

The Novo partnership adds another major pharmaceutical company to Anthropic’s life sciences business as drugmakers increasingly apply AI to research and development.

The Future Forbes Realty Global Properties

Anthropic Unveils Three New Metrics To Track AI Development As Industry Debates A Slowdown

by THEFUTURE.TEAM

September 18, 2026

Anthropic CEO Dario Amodei has called for greater transparency around AI development, including public reporting on how models are built and used.

His proposal reflects a wider debate over the pace of AI development, as capabilities advance while the public and policymakers have limited visibility into how models are trained and improved.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The call has drawn support from OpenAI CEO Sam Altman, Tesla and SpaceX CEO Elon Musk, and Google DeepMind Chair Demis Hassabis. Amodei has said any slowdown should preserve commercial competitiveness and the United States’ lead in AI.

Anthropic Tracks AI Development With Three Metrics

Anthropic said its first metric found that Claude models were not fully autonomous in any subset of the research and development work it measured.

A second metric found roughly 30,000 AI agents performing research and engineering work across the company’s most-used internal platform, with a system in place to monitor and intervene in their actions.

For the third metric, Anthropic examined compute use from July 13 to July 20. About 6% of compute used for AI research and development went to safety, while safety-related work accounted for roughly 12% of compute dedicated to AI-driven research and development.

Why The Metrics Matter

Anthropic said the measures complement capability evaluations by showing more about how AI systems are developed, rather than only what they can do.

The company said publishing the data could give outside observers a clearer basis for assessing the pace of AI development and added that it plans to continue releasing the measurements.